<DOC>
	<DOCNO>NCT02551848</DOCNO>
	<brief_summary>The primary objective study efficacy botulinum toxin type A ( Xeomin® ) inject utilizing kinematically-based injection parameter treatment upper extremity essential tremor ( ET ) . Additional objective study benefit kinematic assessment tool determine injection parameter study composition tremor use kinematics .</brief_summary>
	<brief_title>Botulinum Toxin Type A Injection Bilateral Upper Extremity Tremor Patients With Essential Tremor Using Kinematic Assessment</brief_title>
	<detailed_description />
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Consenting male female participant Diagnosis 'definite essential tremor ' accordance TRIG criterion include : ET individual diagnose upper limb tremor motor dominant nondominant hand Stable ET medication management 3 month duration prior enrollment study Participants botulinum toxin naïve tremor management Patients screen pregnancy physician History stroke Muscle weakness relate compartmental muscle syndrome Smoking History ALS Myasthenia Gravis Offending medication ( Lithium , valproate , steroid , amiodarone , betaadrenergic agonist ( e.g . salbutamol ) Persons prescribe zonisamide History allergic side effect reaction botulinum toxin Contraindications per Xeomin® drug monograph Women reporting pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Movement disorder</keyword>
	<keyword>Botulinum toxin type A</keyword>
	<keyword>Kinematics</keyword>
</DOC>